Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique (IREC), Catholic University of Louvain (UCL), Brussels, Belgium.
Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique (IREC), Catholic University of Louvain (UCL), Brussels, Belgium ; Department of Gastroenterology, Saint-Luc Academic Hospital and Institute of Clinical Research, Catholic University of Louvain, Brussels, Belgium.
J Clin Transl Hepatol. 2015 Mar;3(1):53-66. doi: 10.14218/JCTH.2014.00035. Epub 2015 Mar 15.
Liver fibrosis is part of the wound-healing response to liver damage of various origins and represents a major health problem. Although our understanding of the pathogenesis of liver fibrosis has grown considerably over the last 20 years, effective antifibrotic therapies are still lacking. The use of animal models is crucial for determining mechanisms underlying initiation, progression, and resolution of fibrosis and for developing novel therapies. To date, no animal model can recapitulate all the hepatic and extra-hepatic features of liver disease. In this review, we will discuss the current rodent models of liver injuries. We will then focus on the available ways to target specifically particular compounds of fibrogenesis and on the new models of liver diseases like the humanized liver mouse model.
肝纤维化是各种来源的肝损伤的伤口愈合反应的一部分,是一个主要的健康问题。尽管在过去的 20 年中,我们对肝纤维化发病机制的理解有了很大的提高,但仍然缺乏有效的抗纤维化治疗方法。动物模型的使用对于确定纤维化的起始、进展和消退的机制以及开发新的治疗方法至关重要。迄今为止,没有一种动物模型可以重现所有肝脏和肝脏外疾病的特征。在这篇综述中,我们将讨论目前用于肝脏损伤的啮齿动物模型。然后,我们将重点介绍针对特定纤维化化合物的靶向治疗方法,以及人类化肝脏小鼠模型等新型肝脏疾病模型。